Allen Fienberg, Ph.D., CEO
Dr. Fienberg received his Ph.D. in Human Genetics from Yale University in 1991 and performed post-doctoral studies in neuroscience for over eight years with Nobel Laureate Paul Greengard. During this time Dr. Fienberg published extensively on the generation and implementation of genetic models useful in the study of schizophrenia, Parkinson’s disease and addiction. After a two year stint as a staff scientist at the Genomics Institute of the Novartis Research Foundation, Dr. Fienberg returned to Rockefeller University as a Research Assistant Professor and co-founded Intra-Cellular Therapies with Paul Greengard, Sharon Mates and Moshe Alafi where he became VP for Business Development. As VP Business Development, Dr. Fienberg became familiar with all aspects of growing a company from an early stage start-up, eventually going public and becoming a commercial stage entity. This included fund raising activities, interactions with pharma both in-licensing and out-licensing and interactions with investors. Allen’s strong scientific background should prove essential in communicating the potential of the RUMI technology and in guiding the company at this early stage.